876592-60-8Relevant academic research and scientific papers
Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives
Waterson, Alex G.,Scott, Sarah A.,Kett, Nathan R.,Blobaum, Anna L.,Alex Brown,Lindsley, Craig W.
, p. 3670 - 3673 (2018/10/26)
This letter describes the on-going SAR efforts to develop PLD1, PLD2 and dual PLD1/2 inhibitors with improved physiochemical and disposition properties as well as securing intellectual property position. Previous PLD inhibitors, based on a triazaspiro[4.5
A straightforward and efficiently scaleable synthesis of novel racemic 4-substituted-2,8-diazaspiro[4.5]decan-1-one derivatives
Krafft, Eva A.,Kurt, Anke,Maier, Axel,Thomas, Andrew W.,Zimmerli, Daniel
, p. 3245 - 3252 (2007/10/03)
Novel and straightforward syntheses (3-5 steps, high yields) of racemic diazaspiropiperidine derivatives based on the Michael addition of pipecolate-derived enolates to a range of nitroalkenes have been developed. The reaction has been shown to have a gen
Diaza-spiropiperidine derivatives
-
Page/Page column 8, (2010/02/12)
The present invention relates to compounds of formula wherein A—B, R1, R2, R3, R4, and n are as defined herein; and to pharmaceutically acceptable salts thereof. The compounds of formula I may be used in the tre
Diaza-spiropiperidine derivatives
-
Page/Page column 10, (2010/02/12)
The present invention relates to compounds of formula wherein A-B is —CH2—CH2—, —CH2—O— or —O—CH2—; X is hydrogen or hydroxy; R1 is aryl, optionally substituted by one or two substituents selected fro
